MaxCyte stock, MaxCyte

MaxCyte stock: Q3 revenue jumps 49%, 2026 outlook raised

Published on 11/19/2026 at 04:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
MaxCyte stock enters a new phase after a sharp third-quarter revenue increase. The Akron Bio deal broadens the company's cell-therapy manufacturing offering.

Key developments for investors

  • MaxCyte reported stronger third-quarter revenue and a narrower net loss on November 10.
  • The proposed Akron Bio acquisition would expand MaxCyte's cell-therapy manufacturing offering.
  • Management expects the combined business to have a broader revenue base and improved cash profile.
MaxCyte stock, MaxCyte, quarterly results, revenue guidance, Akron Bio acquisition, cell therapy, Illustration mit AI erstellt.

MaxCyte reported stronger third-quarter results and raised its full-year revenue outlook on November 10, 2026. In the same release, the cell-engineering company announced a proposed acquisition of Akron Bio, a supplier of GMP-grade reagents and ancillary materials for cell-therapy manufacturing. The announcement combines an operating update with a major expansion of MaxCyte's product offering.

According to MaxCyte's earnings release, third-quarter revenue reached 10.2 million US dollars, up 49 percent from the prior-year quarter. Core revenue rose 27 percent to 8.2 million US dollars, while Strategic Platform License program-related revenue increased to 2.0 million US dollars from 0.4 million US dollars.

Gross profit rose to 8.5 million US dollars, producing an 83 percent gross margin versus 77 percent a year earlier. Operating expenses fell to 14.5 million US dollars from 19.4 million US dollars, and the quarterly net loss narrowed to 4.8 million US dollars from 12.4 million US dollars. EBITDA, a non-GAAP measure, remained negative at 5.1 million US dollars.

Akron expands manufacturing reach

MaxCyte agreed to acquire Akron Bio from affiliates of Arcline Investment Management for total consideration of 151.8 million US dollars, according to the company's announcement. Akron is expected to contribute approximately 28 million US dollars of 2026 revenue and 7 million to 8 million US dollars of EBITDA. MaxCyte says the combination would nearly double its revenue base and broaden its presence across the cell-therapy manufacturing workflow.

For standalone MaxCyte, full-year 2026 revenue is now expected to reach at least 34.5 million US dollars, excluding the proposed Akron transaction. The outlook comprises approximately 28 million US dollars of core revenue and at least 6.5 million US dollars from milestones and royalties. MaxCyte ended September with 132.7 million US dollars in cash, cash equivalents and investments.

Business model and competition

MaxCyte is headquartered in Rockville, Maryland, and develops cell-engineering platforms for discovery, development and commercialization of cell-based medicines. Its ExPERT platform includes Flow Electroporation instruments, processing assemblies, software protocols and related support for cell therapy, gene editing, protein and antibody production, vaccines and bioprocessing.

The company operates as a specialized cell-engineering platform provider rather than a broad pharmaceutical manufacturer. Its customers and partners use the technology across research, clinical development and commercial manufacturing, giving MaxCyte exposure to several stages of the cell-therapy market.

MaxCyte company facts

  • Company: MaxCyte, Inc.
  • Ticker: MXCT
  • Home exchange: Nasdaq
  • Headquarters: Rockville, Maryland
  • Third-quarter revenue: 10.2 million US dollars
  • Core revenue: 8.2 million US dollars
  • Quarterly net loss: 4.8 million US dollars

The broader US equity market remains the relevant backdrop for Nasdaq-listed biotechnology and life-science companies; see the S&P 500 market environment.

For further coverage, see More news and analyses on MaxCyte stock.

Disclaimer...
en | boerse | 70533470 |